Background: Inherited thrombocytopenia (IT) contains several forms of familial thrombocytopenia and some of them have propensity to hematological malignancies. The etiological and genetic features of this heterogeneous syndrome have not yet been elucidated.
introduction
Inherited thrombocytopenia (IT) is a general term for several forms of familial thrombocytopenia, including familial platelet disorder with predisposition to acute myelogenous leukemia (FPD/AML; MIM 601399). Epidemiological information is lacking for IT, which has impeded the advance of studies in this field. Importantly, some of the disorders that are categorized into this heterogeneous syndrome show propensity to hematological malignancy. Vigorous research carried out in recent years has provided us with a better understanding and some intriguing aspects of IT. Based on the results of these studies, several novel diseases have been defined by genetic alterations such as mutations in the 5 0 UTR of ANKRD26 (ANKRD26-related thrombocytopenia; ANKRD26-RT) [1, 2] , DDX41 [3] , ETV6 [4, 5] , GATA1 [6] , and GATA2 [7] . Despite these efforts, genetic causes of nearly a half of cases with familial thrombocytopenia are estimated to be unknown [8] and a comprehensive map of this heterogeneous syndrome has not been obtained so far.
FPD/AML is an autosomal-dominant disorder with thrombocytopenia, a tendency toward mild to moderate bleeding, and abnormal platelet function [9] . Most cases occur through a germline mutation in the RUNX1 gene, located at chromosome 21q22, but rare cases develop FPD/AML due to intragenic deletions in RUNX1 or to large deletions at 21q22 [9] [10] [11] [12] . Furthermore, patients with FPD/AML are at risk of hematological malignancies such as myelodysplastic syndrome (MDS) and AML, which affect ∼40% of patients with a median age of onset in the early 30s [13] . Given the incomplete penetrance of malignancy, heterozygous RUNX1 mutations are not sufficient to induce leukemic transformation. We have recently reported that somatic CDC25C mutations are found in ∼50% of FPD/AML patients and that mutated CDC25C disrupts the G2/M checkpoint and promotes the cell cycle under the presence of DNA damage induced by RUNX1 alterations [14] . GATA2 and CBL mutations may also contribute to leukemogenesis in collaboration with RUNX1 and/ or CDC25C mutations in FPD/AML [14, 15] .
The Ministry of Health and Welfare of Japan has promoted studies to elucidate the cause of intractable and/or rare diseases since 1972, and thus, we have conducted a nationwide survey in Japan with the aim of acquiring an epidemiological, clinical, and genetic picture of FPD/AML. We previously reported the results of exome sequencing using the DNA samples of FPD/AML patients who developed hematological malignancies, with support from Grants-in-Aid from the Ministry of Health, Labor, and Welfare of Japan [14] . Individuals who had a history of familial thrombocytopenia and/or hematological malignancies were the target of the survey. However, clinical features of these pedigrees have not been published except some reports of FPD/AML patients [15] [16] [17] [18] . We collected three additional pedigrees, including a new pedigree with FPD/AML (pedigree 58), since our last publication [14] . We added analysis on clinical information of these pedigrees and updated our data with the hope that these observations may provide a tentative guide for clinicians or hematologists who see a thrombocytopenic patient with a familial history of thrombocytopenia that is suspected to be FPD/AML.
materials and methods

study design and subjects
We undertook a postal questionnaire-based, multi-center retrospective study of IT including FPD/AML. A questionnaire was sent to 489 facilities in Japan at a time in November 2010, in which at least one supervisory doctor, certified by the Japanese Society of Hematology, sees patients and provides hematologic training. A reminder letter was sent out when there was no response within 3 months. The enrolled subjects in this study were patients with familial thrombocytopenia and/or familial hematological malignancies, including FPD/AML or with suspected FPD/AML. Considering that FPD/AML is a rare disease and clinicians may not necessarily have experience with it, patients with FPD/AML might have been diagnosed as having immune thrombocytopenia (ITP), MDS, or another similar disorder. Particularly, ITP remains a diagnosis of exclusion and typically, an otherwise healthy individual with thrombocytopenia who does not have grounds related to other causes of thrombocytopenia is diagnosed as ITP [19] . In addition, FPD/AML patients who developed MDS or AML could be also recognized as presenting with sporadic disease, as thrombocytopenia and the bleeding tendency of FPD/ AML are sometimes mild or even absent, and FPD/AML might have been overlooked. Therefore, we also asked clinicians whether they had experience with seeing patients with both thrombocytopenia and family history of thrombocytopenia and/or any type of hematological malignancies (Table 1) .
When a suspected proband was identified, a second questionnaire requesting the detailed clinical features for each patient was sent. A reminder letter was also sent out when there was no response within 3 months. The content of questionnaire is available in supplementary Figure S1 , available at Annals of Oncology online. Bone marrow, peripheral blood, and buccal mucosa samples from subjects were also collected from participating institutions if available. The threshold for thrombocytopenia and bleeding symptoms were determined by a designated individual at each institution. The diagnoses were self-reported by each institute. This study was done in accordance with the Declaration of Helsinki and the ethical guidelines for biomedical research involving human subjects, which were developed by the Ministry of Health, Labor, and Welfare of Japan; the Ministry of Education, Culture, Sports, Science, and Technology of Japan; and the Ministry of Economy, Trade, and Industry of Japan, and enforced on 29 March 2001. This study was approved by the ethics committees of The University of Tokyo and each participating institution. Written informed consent was obtained from all patients whose samples and information were collected after the guideline was enforced.
mutation analysis
Genomic DNA was extracted from the specimens using the QIAamp DNA Mini kit (Qiagen). Polymerase chain reaction (PCR) was carried out using primers for each gene listed in supplementary Table S1 , available at Annals of Oncology online. The products were purified with Illustra ExoStar (GE Healthcare Japan) and sequenced using the BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems) and the ABI Prism 3100 Genetic Analyzer (Life Technologies).
diagnosis
As there have been no definitive criteria for diagnosing FPD/AML, we revised and applied the criteria for the diagnosis of FPD/AML [14] as shown in Table 2 . Conversely, when a mutation was identified in one of the 20 genes (supplementary Table S1 , available at Annals of Oncology online), the subject was tentatively diagnosed as having the mutation-associated disease (such as MYH9-RT).
computer-aided simulation regarding a genetic predisposition to ITP In order to assess whether there was a genetic predisposition to ITP, we ran a computer-aided simulation 10 000 times to calculate how many pedigrees were expected to have X family members with ITP. The epidemiology of ITP in Japan was recently investigated, and the number of patients with ITP was estimated to be ∼20 000 [20] . The total population of Japan was 127 082 000 as of November 2014, and we considered it to be 120 000 000 for simplicity. original articles
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Because it was difficult to define the number and size of pedigrees in Japan (Y = the number of family members in a pedigree), we tested five cases of fixed size for our simulation (Y = 15, 20, 25, 30, and 35). Then we simulated how 20 000 patients were randomly distributed to 120 000 000/Y pedigrees under the hypothesis that there is no genetic predisposition to ITP.
statistical analysis
We compared age in years at diagnosis, sex, and platelet count to seek parameters that are useful to distinguish FPD/AML patients from non-FPD/AML patients. To compare data between groups with equal variances, the unpaired Student's t-test was used. When unequal variances were detected, the Welch's t-test was applied. Variance between groups was compared using the F-test. Categorical variables were compared using Fisher's exact test. Differences were considered statistically significant at P-values of <0.05.
results
The questionnaire was posted to 489 institutions and the response rate was 81.8% (400 institutes) ( Figure 1 ). We collected 72 pedigrees with familial thrombocytopenia and/or hematological malignancies but were supplied with detailed clinical data on 56 pedigrees and with clinical samples on 43 pedigrees. Detailed information and family trees of the 56 pedigrees were shown in Table 3 and supplementary Figure S2 , available at Annals of Oncology online, respectively. Regarding the probands, the median age at initial diagnosis was 41 years old (range: 0-80 years old; Figure 2A ). There were 21 male probands (37.5%) and 35 female probands, and the median platelet count was 59 × 10 9 /l (1-187 × 10 9 /l; Figure 2B ). Bleeding symptoms were observed in 14 probands during their clinical course (25.0%). We did not evaluate platelet aggregation tests because it was not assessed in most cases. At the initial medical examination, 25 probands (44.6%) were diagnosed as having ITP, and 19 probands (33.3%) were diagnosed as having hematological malignancy (10 probands with MDS, 3 with AML, and 5 with lymphoid malignancy; Figure 2C ).
Next, we focused on the 43 pedigrees with clinical samples and found that seven pedigrees (16.3%) with germline RUNX1 mutations were diagnosed as having FPD/AML and one pedigree as suspected FPD/AML (pedigree 32). Note that we tentatively applied strict criteria to diagnosis of FPD/AML as shown in Table 2 and excluded pedigree 32 in order to avoid ambiguity to a maximal extent in our analysis shown below. Among 35 probands who did not have a germline RUNX1 mutation (hereafter, non-FPD/AML), two kinds of MYH9 mutation in pedigrees 11 and 21 (p.Phe41Leu and p.Asp1424Asn, respectively) and one ANKRD26 mutation in pedigree 3 (c.-134G > A) were detected. There were four thrombocytopenic family members other than the proband in pedigree 11 (supplementary Figure S2 , available at Annals of Oncology online). Although Phe41 variants have never been reported and we could not obtain any information about platelet size and morphological abnormality of this pedigree, this variant likely has a pathogenetic significance. On the other hand, Asp1424 mutations are common in MYH9-RT. The proband of pedigree 21 developed diffuse large B-cell lymphoma in the gastrointestinal tract at age 58 and mild thrombocytopenia (71 × 10 9 /l) was also found at the diagnosis of lymphoma (supplemental Figure S2 , available at Annals of Oncology online). However, there was no evidence of infiltration in the bone marrow biopsies nor any causative Age in years at diagnosis means age at diagnosis of thrombocytopenia or hematological malignancies. When a proband had both thrombocytopenia and hematological malignancies, age at diagnosis of the earlier event was used. b A designated individual at each institution determined bleeding symptoms. pathological condition such as disseminated intravascular coagulation. She was also pointed out her thrombocytopenia at age 22 and her brother has thrombocytopenia. From the information above, we diagnosed these two pedigrees as having MYH9-RT. No responsible germline mutation was detected in the other 32 pedigrees. Platelet counts at the initial examination were not significantly different between probands with FPD/AML and non-FPD/AML (P = 0.23; Figure 2D ). Gender, bleeding symptom, and age in years at diagnosis were also comparable (P = 1.0, 0.67, and 0.31, respectively; Figure 2E ). Seventy-one percent of probands with FPD/AML and 51% of non-FPD/AML probands were diagnosed as having hematological malignancies in their clinical course (P = 0.43).
We reviewed the diagnoses of these pedigrees in Table 3 . Among the seven pedigrees with FPD/AML, only one proband (14.3%) was suspected to have FPD/AML at the initial diagnosis. On the contrary, probands in six pedigrees had been initially diagnosed as having FPD/AML, of which a RUNX1 variant was later confirmed in only one (16.7%). Intriguingly, two pedigrees have three and five family members with MDS ( pedigrees 1 and 45, respectively) and there are two additional members with multiple myeloma in pedigree 1. We provisionally diagnosed them as having familial MDS with unknown etiology because of a very strong family history of MDS.
We identified an unexpected accumulation of ITP patients within the pedigrees (five members in pedigree 8, four members in pedigrees 5 and 27, and three members in pedigrees 30, 41, 47, 48, and 56). To evaluate the possibility that such pedigrees with very strong histories of ITP can exist by chance, we ran computer-aided simulation 10 000 times to estimate how 20 000 patients with ITP are randomly distributed to 120 000 000/Y pedigrees in Japan (Y = 15, 20, 25, 30, and 35) under the hypothesis that there is no familial basis in ITP. This simulation revealed that the expected number of pedigrees with four or five affected members is 0-0.0001 or 0, respectively (Figure 3) , which implied that these pedigrees with a strong history of ITP almost never occur by coincidence and that some unknown genetic factors might be associated with these cases of familial thrombocytopenia. Therefore, we diagnosed the three pedigrees ( pedigrees 5, 8, and 27) as having IT with unknown etiology.
discussion
This study is the first nationwide survey that clarified the spectrum of clinical and genetic features of patients with FPD/AML and suspected FPD/AML. Our results underscore the difficulty in distinguishing FPD/AML from other familial or sporadic thrombocytopenia/hematological malignancies based on the patient's clinical information, due to the lack of differences in clinical features ( Figure 2D and E) . In fact, the proportion of positive results for RUNX1 sequencing in suspected pedigrees At the same time, the rate of cases who were suspected to have FPD/AML at initial diagnosis was also low among FPD/AML patients (12.5%). Therefore, genetic analysis of RUNX1 is strongly recommended for patients with suspected FPD/AML. Moreover, non-FPD/AML pedigrees might possess a unique genetic background with a predisposition to thrombocytopenia and/or hematological malignancy, and highthroughput sequencing would contribute to the elucidation of undiscovered genetic mechanisms. Prognosis of FPD/AML who developed MDS or AML is generally poor and AML derived from FPD/AML is almost incurable by conventional chemotherapy. However, there are some papers on successful allogeneic hematopoietic stem cell transplantation (HSCT) for AML derived from FPD/AML [10, 14] . Given that somatic RUNX1 mutations predicted for resistance to chemotherapy and inferior survival and allogeneic HSCT had a favorable impact on treatment outcome in RUNX1-mutated patients [21] , it is speculated that aggressive approaches including allogeneic HSCT should take a priority in the treatment of AML in patients with FPD/ AML. To test RUNX1 and other causative genes that predispose a patient to familial thrombocytopenia and/or hematological malignancies is also essential for future studies of this heterogeneous syndrome, because there have been very limited data on familial thrombocytopenia and hematological malignancies so far. We should continue to make an effort to understand pathogenesis of this syndrome and to seek optimized management for patients with this syndrome. It is controversial whether familial ITP exists. A Swiss group screened a multi-country database (the Pediatric and Adult Registry on Chronic ITP; PARC-ITP) and found that 2.3% of the 445 patients with ITP had a family history of the disease [22] . Although the present study was not designed to estimate the proportion of ITP patients with familial history, we identified eight pedigrees with three or more affected members. Our computeraided simulation showed that these pedigrees are highly unlikely to exist without predisposing factors. In fact, there have been recent reports of the association of single-nucleotide polymorphisms in several genes such as inflammatory cytokine genes, PTPN22, and BAFF with ITP [23] [24] [25] . Intriguingly, there were nine probands who showed a bleeding tendency even though their platelet counts were 3·0 × 10 10 /l or more (pedigrees 3, 4, 5, 8, 11, 19, 23, 39, and 50), which alluded to the possibility that these patients had platelet dysfunctions. Among them, three probands were diagnosed with FPD/AML, MYH9-RT, and ANKRD26-RT. The other four probands were diagnosed as suspected IT (pedigrees 5 and 8) or sporadic ITP (pedigrees 4 and 50) following genetic sequencing. As a limitation of this study, we could not exclude the possibility that possible causal genetic lesions of ITP patients with familial history are undetected at this time. More detailed genetic analysis and functional assays would provide additional information regarding these hereditary forms of familial thrombocytopenia of unknown origin.
We identified two pedigrees with germline MYH9 mutations. MYH9-related disease is a rare disorder caused by inherited MYH9 mutations and characterized by macrothrombocytopenia, giant platelets, leukocyte inclusion, deafness, nephritis, and/ or cataract [26] . Many loss-of-function point mutations were reported within MYH9, and Asp1424, identified in pedigree 21, is a relatively common mutation site as described above. Phe41 mutation, which was detected in pedigree 11 and has never been reported, is an alteration in the globular head domain of MYH9 and may influence its ability to hydrolyze ATP and slide along the actin filament. Mutations in the 5 0 UTR of ANKRD26 were described in families with autosomal-dominant thrombocytopenia [1, 2] , and the mutations have been recently reported to decrease the binding of RUNX1 and FLI1 to the 5 0 UTR, which induced persistent activation of ANKRD26 expression and MAPK signaling as well as impairment of proplatelet formation by megakaryocytes [27] . ANKRD26 mutation in pedigree 3 (c.-134G > A) is one of the more commonly affected sites in ANKRD26-RT. Although ANKRD26-RT is generally characterized by mild bleeding symptoms, the proband of pedigree 3 and two other family members showed bleeding tendencies with their platelet counts being 2-3 × 10 4 /μl. In addition, another family member developed leukemia. These relatively strong phenotypes for ANKRD26-RT might be explained in the context of the degree of activation in ANKRD26 expression and/or MAPK signaling. When we analyzed genomic DNA by Sanger sequencing, we focused on the hotspot(s) of each gene. Therefore, the large rearrangements or rare mutations would be possibly missed and it could underestimate the ability to genetically diagnose some of the subjects. Regarding the diagnosis of FPD/AML, the interpretation of false-positive and false-negative results still remains problematic. For example, it remains to be determined what kind of single-nucleotide variation or deletion of RUNX1 is truly responsible for the platelet abnormality in FPD/AML as previously discussed [14] . On the other hand, it is known that thrombocytopenia is sometimes absent in patients with FPD/AML [10, 17] , which may possibly lead to a false-negative diagnosis. These problems can lead to overestimation or underestimation of FPD/AML prevalence, respectively, that require attention. Additional assays may be useful to diagnose cases with a weak family history and unreported single-nucleotide variants. Interestingly, ANKRD26 expression was suggested to be high in FPD/AML patients [27] . Although it is a preliminary data in a small number of patients (n = 2) and the clinical significance remains to be determined, it may be worth testing usefulness of ANKRD26 expression as a biomarker for the diagnosis of FPD/AML in a larger scale. Such a biomarker could be particularly useful in a patient with suspected FPD/AML who harbors a novel single-nucleotide variation in RUNX1 of unknown pathogenetic significance. When a survey will be carried out on prevalence of FPD/AML in the future, one should pay attention to and cope with the false-positive and false-negative diagnosis, together with some possible biases such as healthcare access bias and non-response bias in postal questionnaires [28] .
In summary, our nationwide survey clarified the difficulty in the diagnosis of FPD/AML on the basis of clinical information. Additional studies involving intensive genetic analysis would be required in the future to gain a better understanding of familial forms of MDS and thrombocytopenia.
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